Novo Nordisk has launched Ozempic, its once-weekly semaglutide injection, in India with prices starting at Rs 8,800. Approved for adults with uncontrolled type-2 diabetes, the drug aids glycaemic control, weight management and reduces cardiovascular and kidney risks.

New Delhi: Novo Nordisk on Friday launched its blockbuster weight-loss drug Ozempic in India, beginning at Rs 8,800 a month or four weeks.

Ozempic — a once-weekly injectable formulation of semaglutide — is approved in India for adults with uncontrolled type 2 diabetes, along with diet and exercise.

The drug is available in three dosage forms — 0.25mg, 0.5 mg, and 1mg — in a single-use pre-filled pen called Novofine Needles designed for painless subcutaneous injection, the drug maker said.

The 0.25 mg, which is the initial

See Full Page